Goldman Sachs Dividend Stocks: Top 14 Stock Picks

12. McKesson Corporation (NYSE:MCK)

On February 18, Barclays raised its price objective on McKesson Corporation (NYSE:MCK) to $1,050 from $960. The firm reiterated an Overweight rating on the shares. Analysts said the stock is expected to “remain in favor” as investors look for “pockets of safety within healthcare.” At the same time, the firm noted that McKesson now trades at a 15% premium to its three-year average.

On January 30, McKesson confirmed it had completed the sale of its retail and distribution businesses in Norway. The buyer was NorgesGruppen, a privately owned retail group. This deal marked an important step in the company’s ongoing restructuring. McKesson had first announced plans on August 4, 2025, to divest its Norway business, which was part of the Other segment. This move represented the final step in its effort to fully exit European operations.

The company said the decision allows it to sharpen its focus. Management plans to direct strategy and capital toward growth areas, especially Oncology, Multispecialty, and Biopharma Services. These segments now form the core of McKesson’s long-term priorities.

McKesson Corporation (NYSE:MCK) operates as a diversified healthcare services company. Its work centers on improving health outcomes and supporting patient care across its network.